Evidence map›Paper›PMID 40308890›Full record

ReviewWorld journal of stem cells2025

Evaluating the efficacy of stem cells in treating severe dry eye disease.

Lanxing Fu, Lucia Pelosini, Nick Kopsachilis, Roberta Foti, Fabiana D'Esposito, Mutali Musa, Alberto D'Amico, Daniele Tognetto, Caterina Gagliano, Marco Zeppieri

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of stem cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lanxing FuDepartment of Ophthalmology, East Kent Hospitals University NHS Foundation Trust, Canterbury CT1 3NG, United Kingdom.
Lucia PelosiniDepartment of Ophthalmology, King's College Hospital NHS Foundation Trust, London SE5 9RS, United Kingdom.
Nick KopsachilisDepartment of Ophthalmology, East Kent Hospitals University NHS Foundation Trust, Canterbury CT1 3NG, United Kingdom.
Roberta FotiDivision of Rheumatology, A.O.U. "Policlinico-San Marco," Catania 95123, Italy.
Fabiana D'EspositoImperial College Ophthalmic Research Group Unit, Imperial College, London NW1 5QH, United Kingdom.
Mutali MusaDepartment of Optometry, University of Benin, Benin 300283, Nigeria.
Alberto D'AmicoAcademic Neurosurgery, Department of Neurosciences, University of Padova, Padova 35128, Italy.
Daniele TognettoDepartment of Medicine, Surgery and Health Sciences, University of Trieste, Trieste 34129, Italy.
Caterina GaglianoDepartment of Medicine and Surgery, University of Enna "Kore," Catania 94100, Italy.
Marco ZeppieriDepartment of Medicine, Surgery and Health Sciences, University of Trieste, Trieste 34129, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dry eye disease (DED) is a multifactorial disorder that disturbs ocular surface equilibrium, considerably diminishing quality of life. Present therapies only offer symptomatic alleviation. Stem cell treatment, especially mesenchymal stem cells (MSCs), has surfaced as a viable approach for tissue regeneration and immunological regulation in DED. Preclinical and early clinical investigations indicate that MSCs can improve lacrimal gland functionality, diminish inflammation, and facilitate corneal regeneration. Nonetheless, obstacles persist in enhancing MSC viability, determining the optimal MSC source, and guaranteeing sustained therapeutic effectiveness. Additional extensive randomized clinical trials are required to confirm the efficacy of MSC-based therapies for severe DED.

Indexed as

Clinical trialsCorneaCorneal regenerationDry eye diseaseExosomeMesenchymal stem cellsStem cell therapy

Identifiers

PMID40308890
PMCPMC12038461

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.